Each year, more than 3 million people are diagnosed with cancers driven by mutations in three RAS-family genes: KRAS, NRAS, and HRAS. RAS-family mutations are associated with numerous types of cancer.
The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...
KRASG12C-targeted therapies like sotorasib and adagrasib have been approved, but resistance challenges persist, necessitating further research into RAS(ON) therapies. Revolution Medicines is ...
The Phase 1 study is a first-in-human, multicenter, open-label trial designed to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of AN9025 in patients with advanced or ...
Early onset metastatic colorectal cancer: Clinical-prognostic characteristics and correlation to molecular profile. This is an ASCO Meeting Abstract from the 2024 ASCO Gastrointestinal Cancers ...
The model suggests that negative KRAS findings are believable when the maximum of APC and TP53 frequencies is at least 8% (corresponding posterior probability of false negative <5%). Validation ...
Daraxonrasib received FDA breakthrough therapy designation for metastatic PDAC with KRAS G12 mutations, expediting its development. The designation is based on promising phase 1 trial results, with ...
The firm is testing the activity of AN9025 in patients with various solid tumors harboring KRAS, NRAS, or HRAS mutations.
Revolution Medicines, Inc. announced that the U.S. FDA has granted Breakthrough Therapy Designation to daraxonrasib, a multi-selective inhibitor targeting KRAS G12 mutations in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results